Dodécavit

Quick links to important sections

Dodécavit

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dodécavit

Quick Facts

Property Description
Active ingredient Hydroxocobalamin (INN)
Form Injectable Solution (Ampoule)
Pharmacological class Anti-anemic Agent / Hematopoietic Factor
Common use Correction of Vitamin B12 deficiency
Origin Synthetic (commercial salt)

Dodécavit is a prescription-only medicine classified as an anti-anemic agent and hematopoietic factor used to supplement the body with the essential nutrient Vitamin B12. Its active ingredient is Hydroxocobalamin (INN), one of the core compounds within the cobalamin family of vitamins. Hydroxocobalamin is clinically recognized for the management of megaloblastic anemia due to B12 deficiency.


What Type of Medicine is Dodécavit and What is its Composition?

Dodécavit is a single-active ingredient cobalamin supplement presented as an injectable solution for parenteral administration. The medicine's composition features Hydroxocobalamin—a form of Vitamin B12—dissolved within an aqueous solution. This formulation is a standard therapeutic choice for B12 replacement therapy because of its efficient retention by the body in comparison to other forms. This sustained retention helps ensure the body can store and utilize the nutrient over time.

This specific parenteral route of administration is necessary to effectively deliver the compound in patients whose underlying conditions, such as pernicious anemia or other forms of malabsorption, prevent adequate uptake of the essential nutrient from the digestive tract.


How Does Hydroxocobalamin Function and What is its General Benefit?

Hydroxocobalamin works by acting as a crucial cofactor required to support two vital biological functions: erythropoiesis (red blood cell formation) and the maintenance of the nervous system. Its use is clinically recognized for reversing the characteristic hematological changes seen in B12 deficiency, as the compound is fundamental for processes like DNA synthesis and the integrity of the myelin sheath surrounding nerve cells.

By supplying this necessary compound, the medicine corrects the underlying nutrient deficit. This action generally helps relieve common deficiency symptoms, which include pronounced fatigue and generalized weakness, by ensuring robust cell replication and supporting overall neurological health.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
  2. Essential Medicine

What side effects are possible with Dodécavit?

Possible Side Effects and Safety Information

The safety profile for Dodécavit (Hydroxocobalamin) is documented based on classifications used by regulatory authorities such as the EMA and FDA. Most adverse reactions for its primary use in B12 deficiency are officially listed as Frequency Not Known, meaning occurrence rates cannot be estimated from available data, though they have been reported in various System-Organ Classes.

Documented Adverse Reactions

Adverse effects are grouped by body system and include reactions within the Immune System (hypersensitivity, rash), Nervous System (headache, tremor), and Gastrointestinal System (nausea, diarrhoea). Reactions affecting the Skin and Subcutaneous Tissue include acneiform eruptions and bullous eruptions. A common, expected, and transient effect is Chromaturia, which is the red coloring of the urine.

Serious Safety Considerations

Officially documented serious adverse reactions include Anaphylaxis, a severe allergic reaction. Additionally, cardiac Arrhythmias (irregular heartbeats) may occur, often secondary to transient Hypokalaemia (low blood potassium) reported during the initial phase of therapy.

Regulatory Safety Notes

Regulatory documents include specific notes regarding patient safety. Individuals with a known cobalt allergy must be vigilant for potential sensitivity reactions, which may be immediate or delayed. A key safety constraint is that high doses may produce a hematological response in patients with an undiagnosed folate deficiency, which could officially mask the true underlying diagnosis.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

Feature Regulatory Statement
Documented overdose presentations The official regulatory profile states that Hydroxocobalamin is not associated with a specific acute toxic overdose syndrome, as excess amounts are cleared via renal excretion. Transient effects may include chromaturia (red coloration of the urine) and skin effects like erythema or rash.
Physiological systems affected (as stated in label) Documented effects include the circulatory system (transient hypertension) and the renal system (potential for acute tubular necrosis with very high exposure).
Dose-related or exposure-related factors (if applicable) Renal excretion is the primary factor preventing a classic toxic overdose, with manifestations like chromaturia being related to high compound elimination.
Population-specific overdose notes (if applicable) Caution is noted for patients with known anaphylactic reactions to cobalamin compounds, as this represents the most severe risk documented in regulatory safety materials.

Emergency-response statements

Classification Regulatory Statement
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for signs of a severe, life-threatening allergic reaction, such as anaphylaxis, swelling of the face, difficulty breathing, or a blistering rash.
Official overdose statements No specific antidote is known; therefore, treatment relies solely on symptomatic and supportive measures. Monitoring of renal function and blood pressure is required following significant exposure due to potential transient changes. The label may advise contacting a regional poison control center for guidance in cases of accidental high exposure.

Connection to the overall overdose profile

Regulatory documents define the overdose profile primarily by the absence of a known acute toxicity syndrome for the compound itself. This context necessitates that emergency help be sought immediately, not for a classic dose-related overdose, but for the onset of life-threatening hypersensitivity symptoms documented in official labels. This is why management relies on symptomatic and supportive treatment and mandated monitoring of renal function and blood pressure.

Therapeutic Uses of Dodécavit

Dodécavit: Main Uses and Benefits

Quick Facts
Therapeutic Domain May be used in the management of nutritional deficiencies.
Primary Indication Supports addressing specific forms of anemia.
Function Used to contribute to the proper function of the nervous system.

Dodécavit is a medication considered for use in patients who require support for certain health requirements, focusing on the maintenance of physiological balance. Its primary therapeutic role involves the addressing of nutritional deficits related to specific biological components.

The medication may be utilized in the clinical management of conditions characterized by particular types of anemia. These uses are designed to assist in maintaining appropriate red blood cell development and function, an essential component of overall health. Additionally, Dodécavit is administered to support the maintenance of nervous system function. This includes assisting in the proper operation of nerve cells and contributing to nerve health.

The medication is intended as part of a therapeutic plan to support the body's requirements and promote appropriate nerve cell activity in established patient populations.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Dodécavit is officially permitted for use in adults and children across the full pediatric age range who have been definitively diagnosed with a Vitamin B12 deficiency. Eligibility for the medicine covers patients with deficiencies resulting from pernicious anemia, gastrointestinal malabsorption syndromes (such as post-gastrectomy), and specific nutritional deficits.


Absolute Contraindications and Exclusions

The medicine is strictly contraindicated and must be withheld from patients with a documented Hypersensitivity (allergy) to Hydroxocobalamin, other Cobalamins (Vitamin B12), or any component within the injectable formulation. Official regulatory documentation specifically identifies a sensitivity to the element Cobalt as a primary basis for non-eligibility.


Conditional Eligibility and Restrictions

Vulnerable Groups:

  • Pregnancy: The medicine is classified as US FDA Category C. Use is only allowed when the therapeutic need is clearly established and outweighs potential risk.
  • Lactation: Use is generally not recommended for breastfeeding mothers. Administration is advised against unless the anticipated benefits of treating the maternal deficiency significantly justify the potential exposure to the infant.

Disease-State Restrictions:

  • Leber's Disease: Use is strongly cautioned and restricted due to the risk of exacerbating the progression of optic nerve atrophy.
  • Severe Anemia: Initial intensive therapy requires mandatory monitoring of serum potassium levels to mitigate the risk of hypokalaemia and secondary cardiac arrhythmias.

Regulatory labels also state that the therapeutic response may be impaired in individuals with concurrent infections or uremia. Treatment may also unmask an underlying disorder such as Polycythaemia Vera.

What should I know about interactions with other medicines?

Dodécavit Interactions with other medicines and products

The interaction profile for Dodécavit, which contains Hydroxocobalamin, is formally defined by regulatory documentation focusing on agents that cause functional antagonism, compromise nutrient status, or require mandatory administration separation.

Pharmacodynamic Interference Interacting Substance Official Interaction Pattern
Nitrous Oxide Causes functional inactivation of the Vitamin B12 coenzyme, creating a risk for neurological complications, such as myelopathy.
Chloramphenicol May formally antagonize the therapeutic hematopoietic response to Vitamin B12 treatment by impairing bone marrow function.

Exposure and Absorption-Modifying Agents The following substances are officially documented to compromise the body’s Vitamin B12 status by inducing malabsorption, a concern even with parenteral administration:

  • Colchicine
  • Para-aminosalicylic acid (PAS)
  • Heavy Alcohol Intake (Chronic use, defined as consumption for longer than two weeks)

Procedural and Timing Restrictions For the injectable solution, strict physical and chemical incompatibility rules apply to co-administration. The following products and solutions must not be administered simultaneously through the same intravenous (IV) line:

  • Sodium Thiosulfate
  • Sodium Nitrite
  • Ascorbic Acid ( Vitamin C)
  • Blood Products (e.g., whole blood, packed cells)

Diagnostic and Population Notes Certain medicines, including Antibiotics, Methotrexate, and Pyrimethamine, are documented to invalidate Vitamin B12 diagnostic blood assays. The risk of severe interaction with Nitrous Oxide is explicitly stated to be heightened in populations with underlying Vitamin B12 deficiency, including the elderly.

Mechanism of Action

Dodécavit, a form of cyanocobalamin, acts as a precursor to the biologically active cofactors methylcobalamin and 5-deoxyadenosylcobalamin within the cytosol. The molecule is transported systemically by plasma protein carriers, primarily transcobalamin II (TCII), which facilitates uptake into target cells via receptor-mediated endocytosis.

Intracellularly, these active cofactors modulate the function of two critical enzymes. Methylcobalamin is an essential cofactor for methionine synthase (MetH), which catalyzes the conversion of homocysteine to methionine. This reaction regenerates tetrahydrofolate (THF) from 5-methyltetrahydrofolate, a process required for nucleotide and DNA synthesis. Separately, 5-deoxyadenosylcobalamin functions as a cofactor for methylmalonyl-CoA mutase (MCM). MCM catalyzes the isomerization of L-methylmalonyl-CoA to succinyl-CoA, an intermediate of the tricarboxylic acid cycle, thereby facilitating the catabolism of odd-chain fatty acids and branched-chain amino acids. System-level physiological modulation occurs through the support of methylation reactions, regulation of DNA precursor synthesis, and integration into mitochondrial energy substrate pathways.

Dosage and Administration Information

The administration of Dodécavit (Hydroxocobalamin injection) follows established protocols defining both the delivery method and the dosage over time. The medicine is intended for parenteral delivery, with the primary route for deficiency treatment being a deep intramuscular (IM) injection administered by a healthcare professional.

Official usage mandates a two-phase schedule to structure replacement therapy. The protocol begins with an initial loading phase, which typically involves administering a dose ranging from 250 mug to 1000 mug of Hydroxocobalamin on an alternate-day frequency for one to two weeks. This intensive phase is designed to replenish the body’s depleted cobalamin stores.

Following the initial treatment, the protocol transitions to a long-term maintenance phase. The standard maintenance dose is 1000 mug, administered at fixed, low-frequency intervals. Depending on the condition, this maintenance injection is typically given every two months or every three months. For underlying conditions causing malabsorption, this maintenance regimen is generally required lifelong.

Procedurally, the solution must be visually inspected for discoloration or particulate matter before administration. Dosage patterns for the pediatric population with macrocytic anaemias often follow the same general initial and maintenance schedules established for adults.

Recent Clinical Evidence

Research evidence / Overview of studies for Dodécavit

Evidence for Use in Vitamin B12 Deficiency and Anemia

Research has examined the use of Dodécavit for conditions involving a lack of essential nutrients in the body, primarily when B12 deficiency is caused by conditions like pernicious anemia or other syndromes that prevent proper absorption in the gut. The foundation of this evidence lies in historical efficacy studies, alongside more recent observational cohort studies that track patient patterns over time. Research examined patients with confirmed low B12 levels and monitored their blood counts, specifically looking at red blood cell formation and size.

Studies described patterns of change in key hematologic parameters that was associated with the move toward expected reference ranges in patients with B12-related anemia following administration. These measurements, such as changes in the size of red blood cells and the number of new red blood cells (reticulocytes), reflect the parameters researchers used to assess changes in blood cell production.


Research on Neurological and Symptomatic Outcomes

Studies have explored outcomes related to systemic or functional imbalance, particularly those concerning nerve health, which may be affected by prolonged B12 deficiency. The research included observational studies and case reports applied in research contexts involving neurological symptoms like loss of sensation or weakness.

Some trials described patterns observed in the studies such as reported shifts in the status of neurological symptoms or an easing of their manifestation. Research highlights changes measured during the study period that were associated with a change in nerve-related symptoms. However, this change was observed in some studies to be dependent on the duration and severity of the underlying deficiency.


Comparative Study Landscape (Injection vs. Other Forms)

Dodécavit, which uses the Hydroxocobalamin form, was evaluated in comparative studies against other forms of B12 and against other administration methods. These studies were primarily RCTs designed to measure pharmacokinetic outcomes, which relate to how the body absorbs, distributes, and retains the compound. Studies reported measurements where the Hydroxocobalamin form exhibited a specific retention pattern in the body, which was observed in some studies during the maintenance phase.


Where Research Remains Limited or Unclear

While the evidence base for Dodécavit is substantial, it has several recognized limitations. A major one is the lack of contemporary RCTs designed to evaluate the short-term symptom resolution against a placebo control. Furthermore, studies often focus on biomarker shifts (like MMA and tHcy levels) rather than patient-reported outcomes describing perceived discomfort or long-term functional status. The link between this correction and the complete resolution of all symptoms for every individual remains uncertain.

Key Studies & References

  1. WHO Model List of Essential Medicines: Hydroxocobalamin
  2. Vitamin B12 (Hydroxocobalamin) Injection - MedlinePlus Drug Information
  3. An update on Vitamin B12 deficiency: Guidelines and clinical management

Frequently Asked Questions (FAQ)

Common questions about Dodécavit (FAQ)

Q: How long does it typically take to notice any effects from Dodécavit?

A: The medicine begins acting in the body immediately after administration. While changes in blood parameters, such as the initial phase of red blood cell formation (reticulocytosis), are typically observed within the first week to ten days, it may take a few weeks before observed changes align with a perceived relief of symptoms.

Q: Is there a maximum length of time people typically stay on Dodécavit?

A: For conditions such as pernicious anemia, the official prescribing information describes that the treatment schedule may be a lifelong regimen. For other types of deficiency, the total length of treatment is determined by a healthcare professional. Decisions about continuing or stopping the treatment are based on the underlying condition and ongoing monitoring.

Q: How does the action of Dodécavit differ from similar generic products?

A: Dodécavit contains Hydroxocobalamin, which is one specific form of Vitamin B12. Studies have described patterns where the Hydroxocobalamin form exhibits a certain sustained retention in the body. This characteristic is described in pharmacological studies as supporting the low-frequency dosing schedule used during the long-term maintenance phase.

Q: Is Dodécavit the same as other similar vitamins or supplements?

A: Dodécavit is not the same as standard oral vitamins or supplements. It is an injectable prescription medicine. The injection is necessary to bypass the digestive tract for patients whose underlying conditions, such as malabsorption, prevent adequate uptake of the essential nutrient from oral forms.

Q: Is it safe for older adults or seniors to use Dodécavit?

A: The eligibility for use is not restricted by age in regulatory documents. However, official information notes that the risk of a severe interaction with Nitrous Oxide is heightened in the elderly population. Additionally, concurrent conditions like infection or uremia may impede the medicine’s therapeutic effect.

Q: Is it safe to drive or operate machinery after taking Dodécavit?

A: The official safety profile for the medicine reports potential side effects affecting the nervous system, such as headache, tremor, and dizziness. The potential for these effects is noted, and patients are advised to discuss with their healthcare provider how these reactions may affect the ability to safely drive or operate machinery.

Q: What is the difference between the brand-name Dodécavit and its generic versions?

A: Dodécavit is a brand-name medicine where the active ingredient is Hydroxocobalamin. An approved generic product will contain the same active ingredient. Differences typically lie in the inactive ingredients (excipients) used in the formulation.

Q: If I feel better, should I continue using Dodécavit as prescribed?

A: For deficiency related to an underlying malabsorption condition like pernicious anemia, treatment is typically a long-term regimen. The regulatory guidelines describe that for an underlying malabsorption condition, the patient is advised to continue the prescribed injection schedule and should not alter therapy based on perceived symptomatic changes.

Q: Does Dodécavit interact with caffeine or alcohol?

A: Official documents on interactions note that heavy and chronic alcohol consumption can compromise the body's overall Vitamin B12 status. However, official regulatory information does not report a direct interaction between the medicine itself and moderate consumption of alcohol or caffeine.

Q: Why do some people report feeling tired after starting Dodécavit?

A: Fatigue and generalized weakness are known symptoms of the Vitamin B12 deficiency that Dodécavit is used to correct. However, unusual tiredness or weakness is also noted in regulatory documents as a reported adverse reaction. Any new or worsening fatigue should be brought to the attention of a healthcare provider.

Q: Is it normal to have a change in appetite while taking this medicine?

A: Anorexia, or a decrease in appetite, is noted in some regulatory documentation as a reported adverse reaction. While the frequency of this specific effect in the B12 deficiency treatment population is not detailed, any change in appetite may be discussed with a treating physician.

Q: Can I take Dodécavit if I am already taking over-the-counter pain relievers?

A: Official prescribing information indicates that Hydroxocobalamin is generally compatible with common over-the-counter pain relievers. However, it is customary to inform the healthcare provider about all non-prescription medicines and supplements being used.

Q: Does Dodécavit need to be taken with food, or does it matter?

A: Since Dodécavit is an injectable solution that is administered directly into the muscle, the medicine is designed to bypass the digestive tract. Therefore, the time of the injection relative to food intake has no impact on its effectiveness or absorption.

Q: If I miss a dose of Dodécavit, what is the generally accepted advice?

A: If the injection is administered by a healthcare professional, contacting the clinic immediately to reschedule the missed appointment is the described procedure. For self-administered injections, the general advice is to administer the dose as soon as it is remembered, with the strong caution that a double dose should not be taken to make up for a missed one.

Q: Are there any foods or beverages that are known to interfere with Dodécavit?

A: Official documents indicate that patients can generally maintain their normal diet and consumption of foods and beverages. The interaction profile highlights pharmaceutical and chemical incompatibilities and severe chronic alcohol use, but does not specify common food items as a concern.

Q: Is Dodécavit available in different forms (e.g., tablet, liquid, injection)?

A: Dodécavit is supplied as an injectable solution in ampoules for parenteral administration by a healthcare professional. It is available only by prescription. Non-injectable forms are not authorized under this specific product name.

Q: What should I do if I think I am experiencing an interaction with another product?

A: If a serious side effect or a potential interaction is suspected, regulatory materials indicate that the patient should contact their doctor or nurse immediately. It is important to disclose all prescription medicines, over-the-counter products, and herbal remedies to the healthcare team.

Q: What happens if Dodécavit is used by someone who doesn't need it?

A: When administered to someone without a diagnosed deficiency, the excess amount of the nutrient is generally eliminated by the body, which can lead to elevated B12 levels. A regulatory note advises that the indiscriminate use of B12 can potentially mask an underlying folic acid deficiency, making the true diagnosis more difficult.

Q: Are there any known issues with taking Dodécavit alongside herbal remedies?

A: Official sources state that there is not enough information to confirm the safety of taking Dodécavit alongside complementary medicines, herbal remedies, or supplements. These products are not tested under the same regulatory requirements as prescription medicines.

Q: Is there a certain time of day that is considered best for taking Dodécavit?

A: Since the medicine is administered as an intramuscular injection, the consistency of the treatment schedule—the correct days and intervals—is the most critical factor. The exact time of day for the injection is not considered a crucial factor for the medicine's absorption or efficacy.

Q: Is Dodécavit commonly stopped and started, or is it typically a continuous treatment?

A: For most patients with an established deficiency, the treatment is typically continuous and long-term. Regulatory notes indicate that discontinuing therapy is only considered after a careful assessment by a healthcare professional for specific asymptomatic patients who meet certain criteria.

Q: Are there known environmental factors that can affect the quality of Dodécavit?

A: Regulatory storage requirements mandate that the solution be kept in the original container, protected from light, and must not be frozen. Separately, the therapeutic effect of the medicine may be impaired in a patient by concurrent factors such as infection or uremia.

Q: Can I travel internationally with Dodécavit?

A: When traveling internationally, general guidance is to keep the medicine in its original, clearly labeled container and carry a copy of the written prescription. Specific regulations regarding travel with injectable medicines and needles can vary by country, so it is advised to check local requirements before travel.

Q: Do I need a prescription to get Dodécavit, or is it available over the counter?

A: Dodécavit is a prescription-only medicine. It is not available for purchase over the counter and must be administered by, or under the guidance of, a healthcare professional.

Q: What are the most common reasons patients discontinue Dodécavit?

A: Discontinuation is rare for most patients, as the medicine is typically a long-term treatment for underlying deficiencies. Discontinuation is only considered after a thorough assessment by a healthcare professional, primarily for asymptomatic patients who meet certain criteria.

Q: What is the intended purpose of Dodécavit, besides the main use?

A: In addition to correcting Vitamin B12 deficiency, the compound is also officially indicated for use as an aid in the Schilling Test, a medical procedure used to help diagnose B12 malabsorption. The same active ingredient is approved in some jurisdictions for use as an antidote for cyanide poisoning.

How should Dodécavit be stored and disposed of?

Storage and Disposal of Dodécavit (Hydroxocobalamin Injection)

The official labeling mandates specific conditions to maintain product stability and ensure safety.

Storage Requirements

Dodécavit must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with limited excursions permitted. It is essential to protect the solution from light and it must not be frozen. The product should be kept in the original container. The medicine must also be stored out of the sight and reach of children.

Stability and Disposal

Do not use the medicine after the labeled expiry date. Any unused medicine in multi-dose vials must be discarded after the designated in-use period (e.g., 28 days). Unused or expired medication, including ampoules and vials, must not be thrown away with household waste or wastewater. Used needles and syringes must be placed into a dedicated sharps container and disposed of according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dodécavit found in:

A-Z Index: